Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Boosted by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG lifted its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 10.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 21,318 shares of the biotechnology company’s stock after acquiring an additional 1,950 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Iovance Biotherapeutics were worth $158,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Impact Partnership Wealth LLC bought a new position in shares of Iovance Biotherapeutics during the fourth quarter worth about $83,000. Clear Creek Financial Management LLC bought a new position in shares of Iovance Biotherapeutics during the fourth quarter worth about $91,000. KBC Group NV grew its position in Iovance Biotherapeutics by 105.7% in the 4th quarter. KBC Group NV now owns 12,303 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 6,321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Iovance Biotherapeutics by 31.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,978 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 2,624 shares in the last quarter. Finally, Assetmark Inc. grew its position in Iovance Biotherapeutics by 48.0% in the 3rd quarter. Assetmark Inc. now owns 12,853 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 4,167 shares in the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Up 4.3 %

Shares of NASDAQ IOVA opened at $5.57 on Friday. Iovance Biotherapeutics, Inc. has a twelve month low of $5.05 and a twelve month high of $18.33. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -3.74 and a beta of 0.53. The firm has a 50-day moving average of $6.72 and a two-hundred day moving average of $8.78.

Wall Street Analyst Weigh In

IOVA has been the subject of a number of recent analyst reports. UBS Group initiated coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. Finally, Piper Sandler decreased their target price on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.69.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.